Your search found 1 Results
Tuberculosis. Testimony of Dr. Kent R. Hill, Assistant Administrator for Global Health, U.S. Agency for International Development, before the Subcommittee on Africa and Global Health, Committee on Foreign Affairs, U.S. House of Representatives, March 21, 2007.
[Unpublished] 2007.  p. (USAID Development Experience Clearinghouse DocID / Order No. PD-ACJ-067)I know we are here to talk about Africa - where the TB problem is indeed severe -- but it is also important and relevant to keep in mind the global TB situation. Sixty percent of the global burden of TB is in the Asia and the Western Pacific regions - notably in countries such as India, China, Indonesia, Bangladesh, Pakistan, The Philippines, Viet Nam, and Cambodia. While many of these countries have made tremendous progress in recent years, there is still much more that needs to be done to ensure sustainability. In Latin America, while there has been much success in controlling TB, sustaining that progress will require TB services reaching the poorest and marginalized groups in all countries. We also can not forget Eastern Europe and Eurasia, where gaining commitment to internationally recognized TB control standards continues to be an uphill struggle. While the recent outbreak of XDR TB in South Africa has made the headlines and must be urgently and effectively dealt with, 17 of the 21 priority countries identified in the WHO's Global MDR and XDR TB response plan are in Asia and the Western Pacific. We must increase attention to Africa, but we can not overlook the other regions where TB is still a serious problem and where MDR and XDR TB are a looming threat. Between 2000 and 2006, USAID provided about $500 million for TB programs worldwide. Our FY 2006 funding level was about $90 million which supported bilateral TB programs in 37 countries (of which 19 are USAID high priority TB countries), as well as other key activities including global surveillance and research on new anti-TB drugs and diagnostics. In FY 2006, USAID provided $5 million to the STOP TB Partnership's Global TB Drug Facility (GDF), an important mechanism that provides drugs to countries in need. Our programs are fully aligned with the new STOP TB Strategy, which builds on the WHO recommended "Directly Observed Treatment, Shortcourse" or DOTS by giving attention to DOTS quality and as well as expansion, TB/HIV-AIDS and MDR TB, engaging all care providers, empowering people with TB and communities, contributing to health system strengthening, and research. (excerpt)